Yıl: 2022 Cilt: 4 Sayı: 3 Sayfa Aralığı: 199 - 205 Metin Dili: İngilizce DOI: 10.36519/idcm.2022.170 İndeks Tarihi: 26-10-2022

Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics

Öz:
Objective: In this study, we aimed to determine and compare the rates of empirical antibiotic use and duration between the chest diseases clinic (CDC), infectious disease clinic (IDC), and internal medicine clinic (IMC) among patients hospitalized because of COVID-19. Methods: This cross-sectional study was performed in a single university hospital. The study included all patients aged 18 years and older hospitalized with a PCR-confirmed COVID-19 between May 30, 2021, and August 30, 2021. Clinical and laboratory findings were recorded from the electronic medical records database. Results: The study included a total of 581 inpatients, of whom 310 (53.4%) were women. Of the 581 patients, 475 (81.8%) were prescribed antibiotics. The rate of antibiotic prescription was 71.6% for IDC, 88.5% for CDC, and 87.4% for IMC. The most commonly used antibiotic was moxifloxacin in all groups. The mean treatment duration was 8.9±6.16 days. The mean duration of antibiotic treatment was 11.1±5.90 days for CDC, 11.3±6.74 days for IMC, and 5.3 days±3.76 for IDC. Conclusion: Patients with COVID-19 who were treated in IDC had a lower rate and shorter duration of antibiotic use compared to the other clinics. However, the rate of antibiotic prescription in all three groups was very high. Therefore, antimicrobial management programs should be meticulously conducted to reduce unnecessary antibiotic use.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda: National Library of Medicine (NIH). (updated August 18, 2022; cited December 27, 2021). Available from: https://www.ncbi.nlm.nih.gov/books/NBK570371/
  • Poston JT, Patel BK, Davis AM. Management of critically Ill adults with COVID-19. JAMA. 2020;323(18):1839-41. [CrossRef]
  • Beović B, Doušak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386- 90. [CrossRef]
  • Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-10. [CrossRef]
  • Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085-6. [CrossRef]
  • Subramanya SH, Czyż DM, Acharya KP, Humphreys H. The potential impact of the COVID-19 pandemic on antimicrobial resistance and antibiotic stewardship. VirusDisease. 2021;32(2):330-7. [CrossRef]
  • Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75(7):1681-4. [CrossRef]
  • Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am. 2011;25(1):245-60. [CrossRef]
  • Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. J Infect. 2020;81(3):e55-e7. [CrossRef]
  • Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda: National Library of Medicine (NIH). (updated December 16, 2021; cited December 27, 2021). Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/covid19treatmentguidelines-12-16-2021.pdf
  • Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in Metropolitan Detroit. JAMA Netw Open. 2020;3(6):e2012270. [CrossRef]
  • Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020;81(6):952-60. [CrossRef]
  • Kokturk N, Babayigit C, Kul S, Duru Cetinkaya P, Atis Nayci S, Argun Baris S, et al. The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. Respir Med. 2021;183:106433. [CrossRef]
  • Birtay T, Bahadir S, Kabacaoglu E, Yetiz O, Demirci MF, Genctoy G. Prognosis of patients hospitalized with a diagnosis of COVID-19 pneumonia in a tertiary hospital in Turkey. Ann Saudi Med. 2021;41(6):327-35. [CrossRef]
  • Bendala Estrada AD, Calderón Parra J, Fernández Carracedo E, Muiño Míguez A, Ramos Martínez A, Muñez Rubio E, et al. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infect Dis. 2021;21(1):1144. [CrossRef]
  • Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van Apeldoorn M, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond). 2021;53(2):102-10. [CrossRef]
  • Hoşoğlu S, Esen S, Ozturk R, Altindis M, Ertek M, Kaygusuz S, et al. The effect of a restriction policy on the antimicrobial consumption in Turkey: a country-wide study. Eur J Clin Pharmacol. 2005;61(10):727-31. [CrossRef]
  • Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12. [CrossRef]
  • Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020;51(7):741-2. [CrossRef]
  • Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-9. [CrossRef]
  • Bassetti M, Giacobbe DR, Bruzzi P, Barisione E, Centanni S, Castaldo N, et al; Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clinical management of adult patients with COVID-19 outside intensive care units: guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2021;10(4):1837-85. [CrossRef]
  • Townsend L, Hughes G, Kerr C, Kelly M, O’Connor R, Sweeney E, et al. Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC Antimicrob Resist. 2020;2(3):dlaa071. Erratum in: JAC Antimicrob Resist. 2020;2(4):dlaa095. [CrossRef]
APA evlice o, ŞENER A, MISTANOGLU OZATAG D, Ak O, BEKTAS M, ARIK Ö, Acet A, marım f, Kaya I (2022). Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. , 199 - 205. 10.36519/idcm.2022.170
Chicago evlice oğuz,ŞENER Aziz,MISTANOGLU OZATAG DURU,Ak Oznur,BEKTAS MURAT,ARIK ÖZLEM,Acet Aycan,marım feride,Kaya Ilknur Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. (2022): 199 - 205. 10.36519/idcm.2022.170
MLA evlice oğuz,ŞENER Aziz,MISTANOGLU OZATAG DURU,Ak Oznur,BEKTAS MURAT,ARIK ÖZLEM,Acet Aycan,marım feride,Kaya Ilknur Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. , 2022, ss.199 - 205. 10.36519/idcm.2022.170
AMA evlice o,ŞENER A,MISTANOGLU OZATAG D,Ak O,BEKTAS M,ARIK Ö,Acet A,marım f,Kaya I Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. . 2022; 199 - 205. 10.36519/idcm.2022.170
Vancouver evlice o,ŞENER A,MISTANOGLU OZATAG D,Ak O,BEKTAS M,ARIK Ö,Acet A,marım f,Kaya I Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. . 2022; 199 - 205. 10.36519/idcm.2022.170
IEEE evlice o,ŞENER A,MISTANOGLU OZATAG D,Ak O,BEKTAS M,ARIK Ö,Acet A,marım f,Kaya I "Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics." , ss.199 - 205, 2022. 10.36519/idcm.2022.170
ISNAD evlice, oğuz vd. "Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics". (2022), 199-205. https://doi.org/10.36519/idcm.2022.170
APA evlice o, ŞENER A, MISTANOGLU OZATAG D, Ak O, BEKTAS M, ARIK Ö, Acet A, marım f, Kaya I (2022). Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. Infectious diseases and clinical microbiology (Online), 4(3), 199 - 205. 10.36519/idcm.2022.170
Chicago evlice oğuz,ŞENER Aziz,MISTANOGLU OZATAG DURU,Ak Oznur,BEKTAS MURAT,ARIK ÖZLEM,Acet Aycan,marım feride,Kaya Ilknur Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. Infectious diseases and clinical microbiology (Online) 4, no.3 (2022): 199 - 205. 10.36519/idcm.2022.170
MLA evlice oğuz,ŞENER Aziz,MISTANOGLU OZATAG DURU,Ak Oznur,BEKTAS MURAT,ARIK ÖZLEM,Acet Aycan,marım feride,Kaya Ilknur Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. Infectious diseases and clinical microbiology (Online), vol.4, no.3, 2022, ss.199 - 205. 10.36519/idcm.2022.170
AMA evlice o,ŞENER A,MISTANOGLU OZATAG D,Ak O,BEKTAS M,ARIK Ö,Acet A,marım f,Kaya I Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. Infectious diseases and clinical microbiology (Online). 2022; 4(3): 199 - 205. 10.36519/idcm.2022.170
Vancouver evlice o,ŞENER A,MISTANOGLU OZATAG D,Ak O,BEKTAS M,ARIK Ö,Acet A,marım f,Kaya I Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics. Infectious diseases and clinical microbiology (Online). 2022; 4(3): 199 - 205. 10.36519/idcm.2022.170
IEEE evlice o,ŞENER A,MISTANOGLU OZATAG D,Ak O,BEKTAS M,ARIK Ö,Acet A,marım f,Kaya I "Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics." Infectious diseases and clinical microbiology (Online), 4, ss.199 - 205, 2022. 10.36519/idcm.2022.170
ISNAD evlice, oğuz vd. "Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics". Infectious diseases and clinical microbiology (Online) 4/3 (2022), 199-205. https://doi.org/10.36519/idcm.2022.170